AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36164681 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Number of subjects: 156
Study 34147510 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social comparison
Number of subjects: 254
Study 34147510 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social comparison
Number of subjects: 254
Study 34147510 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative general
Number of subjects: 254
Study 34147510 — intervention group
Group type: COMPARATOR
Intervention: Neutral (control)
Number of subjects: 254
Study 35858943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-spraying probiotics containing 5 billion Bacillus spores (LiveSpo Navax)
Number of subjects: 40
Study 35858943 — intervention group
Group type: COMPARATOR
Intervention: Control-standard of care
Number of subjects: 40
Study 35858943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-spraying probiotics (LiveSpo Navax)
Number of subjects: 40
Study 32553279 — intervention group
Group type: COMPARATOR
Intervention: Low Dose (LD) group, 80 kV with a NI of 25 and iohexol (350 mg I/ml)
Number of subjects: 180
Study 32553279 — intervention group
Group type: COMPARATOR
Intervention: Further Low Dose (FLD) group, 80 kV with a NI of 30 and iomeprol (400 mg I/ml)
Number of subjects: 180
Study 32553279 — intervention group
Group type: COMPARATOR
Intervention: Low Dose (LD) group
Number of subjects: 180
Study 32553279 — intervention group
Group type: COMPARATOR
Intervention: Further Low Dose (FLD) group
Number of subjects: 180
Study 32553279 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Dose (CD) group, 100 kV with a NI of 25 and iohexol (350 mg I/ml)
Number of subjects: 180
Study 35674733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg/day)
Number of subjects: 64
Study 33655929 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Focus
Number of subjects: 12
Study 33655929 — intervention group
Group type: COMPARATOR
Intervention: External Focus
Number of subjects: 12
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma detection rate (ADR)
Number of subjects: 2889
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal serrated polyp detection rate (PSPDR)
Number of subjects: 2889
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of optical diagnosis for adenomas
Number of subjects: 2889
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of optical diagnosis for serrated polyps
Number of subjects: 2889
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ADR and sensitivity of optical diagnosis for adenomas
Number of subjects: 2889
Study 32349138 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PSPDR and sensitivity of optical diagnosis for serrated polyps
Number of subjects: 2889
Study 35894487 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with 1 minute wait
Number of subjects: 123
Study 35894487 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block (PCB) with 3 minutes wait
Number of subjects: 123
Study 35894487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 35894487 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs with 60 minutes wait
Number of subjects: 123
Study 34610185 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressing
Number of subjects: 307
Study 34610185 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 307
Study 32715442 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane with UGT2B17 gene deletion
Number of subjects: 1752
Study 32715442 — intervention group
Group type: COMPARATOR
Intervention: Placebo with UGT2B17 gene deletion
Number of subjects: 1752
Study 32715442 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane with lower metabolite ratio (poor detoxification)
Number of subjects: 1752
Study 36408023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab plus chemotherapy (SC)
Number of subjects: 0
Study 36408023 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (PC)
Number of subjects: 0
Study 33002839 — intervention group
Group type: EXPERIMENTAL
Intervention: BWS with visual feedback stimulation (Experimental VF+ group)
Number of subjects: 63
Study 33002839 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced BWS gait training sessions without visual feedback (Experimental VF- group)
Number of subjects: 63
Study 33002839 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 63
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% (40mg at 64mL gel; n=20)
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% (80mg at 64mL gel; n=22)
Number of subjects: 64
Study 616357443 — intervention group
Group type: COMPARATOR
Intervention: MMC 0.1% (40mg in 40mL water; n=23)
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for tumors <=1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for tumors <=1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: COMPARATOR
Intervention: MMC 0.1% for tumors <=1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for tumors >1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for tumors >1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: COMPARATOR
Intervention: MMC 0.1% for tumors >1cm²
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for patients with <=3 tumors
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for patients with <=3 tumors
Number of subjects: 64
Study 616357443 — intervention group
Group type: COMPARATOR
Intervention: MMC 0.1% for patients with <=3 tumors
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.06% for patients with >3 tumors
Number of subjects: 64
Study 616357443 — intervention group
Group type: EXPERIMENTAL
Intervention: VesiGel 0.12% for patients with >3 tumors
Number of subjects: 64
Study 616357443 — intervention group
Group type: COMPARATOR
Intervention: MMC 0.1% for patients with >3 tumors
Number of subjects: 64
Study 35143041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening (LCS)
Number of subjects: 843
Study 33748882 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (factual explanation of MRI report)
Number of subjects: 44
Study 33748882 — intervention group
Group type: COMPARATOR
Intervention: Group B (reassured that MRI findings showed normal changes)
Number of subjects: 44
Study 33748882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reporting method
Number of subjects: 44
Study 33748882 — intervention group
Group type: COMPARATOR
Intervention: Routine MRI reporting
Number of subjects: 44
Study 35368016 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape decompression/fan application with standard therapy
Number of subjects: 14
Study 35368016 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with no kinesiology tape (Control)
Number of subjects: 14
Study 34112732 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day group
Number of subjects: 90
Study 34112732 — intervention group
Group type: COMPARATOR
Intervention: Bacterial load-guided group (BLGG)
Number of subjects: 90
Study 32690830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% curcumin gel
Number of subjects: 25
Study 32690830 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel
Number of subjects: 25
Study 34716525 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized group (lesions applied to the anterior/posterior carina and the ridge between the left atrial appendage and the left pulmonary vein, followed by continuous lesions)
Number of subjects: 100
Study 34716525 — intervention group
Group type: COMPARATOR
Intervention: Sequential group (continuous circular lesions created counter-clockwise starting from the site of 6 o'clock)
Number of subjects: 100
Study 32619497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin prescription
Number of subjects: 526
Study 32619497 — intervention group
Group type: COMPARATOR
Intervention: T2DM without metformin prescription
Number of subjects: 526
Study 32619497 — intervention group
Group type: COMPARATOR
Intervention: Non-T2DM patients
Number of subjects: 526
Study 36384562 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (IFX + MTX)
Number of subjects: 60
Study 36384562 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (hydroxychloroquine, sulphasalazine, and methotrexate) (TRIPLE)
Number of subjects: 60
Study 36384562 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (MTX)
Number of subjects: 60
Study 33281442 — intervention group
Group type: EXPERIMENTAL
Intervention: XBJ
Number of subjects: 0
Study 33281442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36129221 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 105
Study 36129221 — intervention group
Group type: COMPARATOR
Intervention: No Patient Decision Aid (Control)
Number of subjects: 105
Study 33972448 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption during social interaction
Number of subjects: 20000
Study 33972448 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 20000
Study 33172390 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with PVT
Number of subjects: 78
Study 35704559 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM: 250mg), once-weekly weight-based dose of 1-5 tablets, taken orally.
Number of subjects: 347
Study 35704559 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken orally.
Number of subjects: 347
Study 35704559 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM: 250mg)
Number of subjects: 347
Study 34413300 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint inhibitors (ICIs)
Number of subjects: 72
Study 34413300 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 72
Study 32571649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT) with passive self-ligating brackets
Number of subjects: 65
Study 32571649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT) with conventional brackets
Number of subjects: 65
Study 32571649 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional brackets without LLLT)
Number of subjects: 65
Study 35817323 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy/15 fractions/3 weeks (control for simultaneous integrated boost)
Number of subjects: 271
Study 35817323 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Gy/5 fractions/1 week (experimental for simultaneous integrated boost)
Number of subjects: 271
Study 35817323 — intervention group
Group type: COMPARATOR
Intervention: 12 Gy/4 fractions/4 days (for sequential boost)
Number of subjects: 271
Study 34172540 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Active Rest Programme (WARP)
Number of subjects: 29
Study 34172540 — intervention group
Group type: COMPARATOR
Intervention: Control (usual activities)
Number of subjects: 29
Study 32224802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological pupil dilatation
Number of subjects: 106
Study 33797858 — intervention group
Group type: EXPERIMENTAL
Intervention: Art-training group (n = 43) attended four 1-hour sessions to solve technical drawing worksheets
Number of subjects: 84
Study 33797858 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 84
Study 33797858 — intervention group
Group type: EXPERIMENTAL
Intervention: Art-training group (n = 43)
Number of subjects: 84
Study 34873925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 3056
Study 34873925 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 3056
Study 1987034936 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant interferon-alpha
Number of subjects: 18
Study 34343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counselling intervention
Number of subjects: 192
Study 34343051 — intervention group
Group type: COMPARATOR
Intervention: Conventional case management (Control)
Number of subjects: 192
Study 34673895 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/d of intravenous dexamethasone
Number of subjects: 1000
Study 34673895 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/d of intravenous dexamethasone
Number of subjects: 1000
Study 32372161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (5%) 4 times daily for 14 days
Number of subjects: 183
Study 32372161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (5%)
Number of subjects: 183
Study 35486517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic augmented (DA) ACL suture repair (ACLSR)
Number of subjects: 48
Study 35486517 — intervention group
Group type: COMPARATOR
Intervention: Anatomic single-bundle ACL reconstruction (ACLR)
Number of subjects: 48
Study 33910581 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%)
Number of subjects: 100716
Study 32540553 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily)
Number of subjects: 60
Study 35546102 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 2672
Study 33336844 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI-bevacizumab
Number of subjects: 317
Study 33336844 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-panitumumab
Number of subjects: 317
Study 35279890 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 0
Study 35279890 — intervention group
Group type: COMPARATOR
Intervention: Brodalumab 210 mg after brodalumab 140 mg or placebo
Number of subjects: 0
Study 34124244 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum uric acid level
Number of subjects: 0
Study 34124244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum uric acid level
Number of subjects: 0
Study 34124244 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined uric acid levels
Number of subjects: 0
Study 32367870 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg oral misoprostol
Number of subjects: 100
Study 32367870 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 100
Study 35793047 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily alogliptin/metformin combination tablet (alogliptin 25 mg/metformin 500 mg)
Number of subjects: 48
Study 35793047 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily anagliptin/metformin combination tablet low dose (anagliptin 100 mg/metformin 250 mg)
Number of subjects: 48
Study 33342526 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed Promise intervention (home-delivered food boxes with $38 food value and $15 check for fruits and vegetables)
Number of subjects: 4750
Study 33342526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4750
Study 33610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted relative carbohydrate intake (E%)
Number of subjects: 268922
Study 33610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted dietary intake of fat (E%)
Number of subjects: 268922
Study 33610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 268922
Study 33610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 268922
Study 35671902 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Eats intervention (n = 24)
Number of subjects: 48
Study 35671902 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) comparison group (n = 24)
Number of subjects: 48
Study 32066254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri CRL1324, Lactobacillus gasseri CRL1263 and CRL1307
Number of subjects: 3
Study 32066254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CRL1332, L. gasseri CRL1256 and CRL1320
Number of subjects: 3
Study 32066254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 36353762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir 1200 mg
Number of subjects: 605
Study 36353762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 34191244 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxis Good Behavior Game (PaxGBG)
Number of subjects: 0
Study 34191244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional prevention initiatives promoting evidence-based practices
Number of subjects: 0
Study 32717448 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP block
Number of subjects: 80
Study 32717448 — intervention group
Group type: COMPARATOR
Intervention: Control (fentanyl only)
Number of subjects: 80
Study 35977732 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Work and Life (SWAL) intervention
Number of subjects: 756
Study 35977732 — intervention group
Group type: EXPERIMENTAL
Intervention: SWAL intervention with a height adjustable desk (SWAL plus desk)
Number of subjects: 756
Study 35977732 — intervention group
Group type: EXPERIMENTAL
Intervention: SWAL plus desk
Number of subjects: 756
Study 35977732 — intervention group
Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 756
Study 35977732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (SWAL and SWAL plus desk)
Number of subjects: 756
Study 33218568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 24
Study 33685864 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg thrice weekly
Number of subjects: 326
Study 33685864 — intervention group
Group type: COMPARATOR
Intervention: Maxacalcitol 5 or 10 µg thrice weekly
Number of subjects: 326
Study 32845519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NVX‐207
Number of subjects: 8
Study 32845519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% BA
Number of subjects: 8
Study 32845519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 35452478 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention (two-hour workshop + optional 24-week online program)
Number of subjects: 40
Study 35452478 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 33727260 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (AD)
Number of subjects: 60
Study 33727260 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation + palbociclib (AD + palbociclib)
Number of subjects: 60
Study 35812818 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality experience during haemodialysis (4-week intervention period with 12 sessions)
Number of subjects: 40
Study 35812818 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group during 4-week control period)
Number of subjects: 40
Study 33761804 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label once daily subcutaneous vosoritide combined with standard of care
Number of subjects: 20
Study 33761804 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 20
Study 35276810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate (equiv. iron 24 mg) with folinic acid and multivitamins (test group, n = 60)
Number of subjects: 120
Study 35276810 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (equiv. iron 66 mg, control group, n = 60)
Number of subjects: 120
Study 35276810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate with folinic acid (test group)
Number of subjects: 120
Study 35276810 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (control group)
Number of subjects: 120
Study 34387246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid
Number of subjects: 34
Study 34387246 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 34952877 — intervention group
Group type: EXPERIMENTAL
Intervention: subacromial impingement syndrome
Number of subjects: 1308
Study 34952877 — intervention group
Group type: EXPERIMENTAL
Intervention: rotator cuff tear
Number of subjects: 1308
Study 34952877 — intervention group
Group type: EXPERIMENTAL
Intervention: bursitis
Number of subjects: 1308
Study 34952877 — intervention group
Group type: EXPERIMENTAL
Intervention: shoulder sprain
Number of subjects: 1308
Study 34952877 — intervention group
Group type: EXPERIMENTAL
Intervention: episode of shoulder pain
Number of subjects: 1308
Study 32833549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (ONS)
Number of subjects: 0
Study 32833549 — intervention group
Group type: COMPARATOR
Intervention: Routine Treatment (RT)
Number of subjects: 0
Study 33063570 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 134
Study 33063570 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 134
Study 35835435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact grafts (SCR or BG)
Number of subjects: 50
Study 32109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sample from the sexual violence prevention program
Number of subjects: 10135
Study 32109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who complied with RCT protocol
Number of subjects: 10135
Study 32109784 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with a history of victimization or perpetration of sexual violence
Number of subjects: 10135
Study 35503613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 120
Study 35503613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (HIIT)
Number of subjects: 120